Mechanisms for Organ Dysfunction in Covid-19

COVID-19 Clinical Trial

— UMODCOVID19  

Official title:

Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04316884
• Other study ID #: EPN 2017/043 Covid19
• Status: Recruiting
• Start date: March 12, 2020
• Est. completion date: December 31, 2026

Study information

• Verified date: May 2024
• Source: Uppsala University
• Contact: Robert Frithiof, MD. PhD.
• Phone: 0736563473
• Email: robert.frithiof[@]surgsci.uu.se
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.

Description:

Consenting patients with suspected or verified SARS-COV-2 infection, COVID-19, will undergo daily blood, urine and sputum sampling during their stay in intensive care. Data on organ dysfunction will be collected through the electronic patient journal and electronic patient data management system. The collected samples will be analysed for a panel of potential biomarkers that will be correlated to organ dysfunction and clinical outcome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Admitted to intensive care
• suspected or verified COVID-19

Exclusion Criteria:

• Pregnancy or breastfeeding
• Under-age

Related Conditions & MeSH terms

• Acute Kidney Injury
• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• COVID-19
• Multiple Organ Failure
• Organ Dysfunction Syndrome Sepsis
• Organ Dysfunction Syndrome, Multiple
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Septic Shock
• Syndrome
• Systemic Inflammatory Response Syndrome

Locations

Country	Name	City	State
Sweden	Uppsala University Hospital	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
Uppsala University

Country where clinical trial is conducted

Sweden, 

References & Publications (22)

Asif S, Frithiof R, Lipcsey M, Kristensen B, Alving K, Hultstrom M. Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care. Crit Care. 2020 Nov 6;24(1):639. doi: 10.1186/s13054-020-033 — View Citation

Bulow Anderberg S, Lipcsey M, Hultstrom M, Eriksson AK, Venge P, Frithiof R, On Behalf Of The Uppsala Intensive Care Covid-Research Group. Systemic Human Neutrophil Lipocalin Associates with Severe Acute Kidney Injury in SARS-CoV-2 Pneumonia. J Clin Med. — View Citation

Bulow Anderberg S, Luther T, Berglund M, Larsson R, Rubertsson S, Lipcsey M, Larsson A, Frithiof R, Hultstrom M. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 202 — View Citation

COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021 Dec;600(7889):472-477. doi: 10.1038/s41586-021-03767-x. Epub 2021 Jul 8. — View Citation

Eriksson O, Hultstrom M, Persson B, Lipcsey M, Ekdahl KN, Nilsson B, Frithiof R. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemost. 2020 Dec;120(12):1720-1724. doi: 10.1055/s-0040-171 — View Citation

Frithiof R, Bergqvist A, Jarhult JD, Lipcsey M, Hultstrom M. Presence of SARS-CoV-2 in urine is rare and not associated with acute kidney injury in critically ill COVID-19 patients. Crit Care. 2020 Sep 29;24(1):587. doi: 10.1186/s13054-020-03302-w. No abs — View Citation

Frithiof R, Rostami E, Kumlien E, Virhammar J, Fallmar D, Hultstrom M, Lipcsey M, Ashton N, Blennow K, Zetterberg H, Punga AR. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin Neurophysiol. — View Citation

Galien S, Hultstrom M, Lipcsey M, Stattin K, Frithiof R, Rosen J; Uppsala Intensive Care COVID-19 Research Group. Point of care ultrasound screening for deep vein thrombosis in critically ill COVID-19 patients, an observational study. Thromb J. 2021 Jun 2 — View Citation

Gradin A, Andersson H, Luther T, Anderberg SB, Rubertsson S, Lipcsey M, Aberg M, Larsson A, Frithiof R, Hultstrom M. Urinary cytokines correlate with acute kidney injury in critically ill COVID-19 patients. Cytokine. 2021 Oct;146:155589. doi: 10.1016/j.cy — View Citation

Huckriede J, Anderberg SB, Morales A, de Vries F, Hultstrom M, Bergqvist A, Ortiz-Perez JT, Sels JW, Wichapong K, Lipcsey M, van de Poll M, Larsson A, Luther T, Reutelingsperger C, de Frutos PG, Frithiof R, Nicolaes GAF. Evolution of NETosis markers and D — View Citation

Huckriede J, de Vries F, Hultstrom M, Wichapong K, Reutelingsperger C, Lipcsey M, Garcia de Frutos P, Frithiof R, Nicolaes GAF. Histone H3 Cleavage in Severe COVID-19 ICU Patients. Front Cell Infect Microbiol. 2021 Sep 10;11:694186. doi: 10.3389/fcimb.202 — View Citation

Hultstrom M, Persson B, Eriksson O, Lipcsey M, Frithiof R, Nilsson B. Blood type A associates with critical COVID-19 and death in a Swedish cohort. Crit Care. 2020 Aug 12;24(1):496. doi: 10.1186/s13054-020-03223-8. No abstract available. — View Citation

Hultstrom M, von Seth M, Frithiof R. Hyperreninemia and low total body water may contribute to acute kidney injury in COVID-19 patients in intensive care. J Hypertens. 2020 Aug;38(8):1613-1614. doi: 10.1097/HJH.0000000000002531. No abstract available. — View Citation

Jarhult JD, Hultstrom M, Bergqvist A, Frithiof R, Lipcsey M. The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. Sci Rep. 2021 Mar 30;11(1):7163. doi: 10.1038/s41598-021-86500-y. — View Citation

Karawajczyk M, Douhan Hakansson L, Lipcsey M, Hultstrom M, Pauksens K, Frithiof R, Larsson A. High expression of neutrophil and monocyte CD64 with simultaneous lack of upregulation of adhesion receptors CD11b, CD162, CD15, CD65 on neutrophils in severe CO — View Citation

Lipcsey M, Persson B, Eriksson O, Blom AM, Fromell K, Hultstrom M, Huber-Lang M, Ekdahl KN, Frithiof R, Nilsson B. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. Front Immunol. 20 — View Citation

Luther T, Bulow-Anderberg S, Larsson A, Rubertsson S, Lipcsey M, Frithiof R, Hultstrom M. COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury. Acta Anaesthesiol Scand. 2021 Mar;65(3):364-372. doi: 10.1111/aas.13746. Epub — View Citation

Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, Bujanda L, Bouysran Y, Niemi ME, Palom A, Ellinghaus D, Khan A, Martinez-Bueno M, Rolker S, Amitrano S, Roade Tato L, Fava F; FinnGen; COVID-19 Host Genetics Initiative (H — View Citation

Pellegrini M, Larina A, Mourtos E, Frithiof R, Lipcsey M, Hultstrom M, Segelsjo M, Hansen T, Perchiazzi G. A quantitative analysis of extension and distribution of lung injury in COVID-19: a prospective study based on chest computed tomography. Crit Care. — View Citation

Sancho Ferrando E, Hanslin K, Hultstrom M, Larsson A, Frithiof R, Lipcsey M; Uppsala Intensive Care COVID-19 Research Group. Soluble TNF receptors predict acute kidney injury and mortality in critically ill COVID-19 patients: A prospective observational s — View Citation

Stattin K, Lipcsey M, Andersson H, Ponten E, Bulow Anderberg S, Gradin A, Larsson A, Lubenow N, von Seth M, Rubertsson S, Hultstrom M, Frithiof R. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients. J Crit C — View Citation

Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, Laurent L, Pietzner M, Kerrison N, Zhao K, Brunet-Ratnasingham E, Henry D, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, A — View Citation

* Note: There are 22 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acute Kidney Injury	KDIGO AKI score	During Intensive Care, an estimated average of 10 days.
Secondary	ARDS	Acute Respiratory Distress Syndrome yes/no	During intensive care, an estimated average of 10 days.
Secondary	30 day mortality	Death within 30 days of ICU admission	30 days
Secondary	1 year mortality	Death within 1 year of ICU admission	1 year
Secondary	Chronic Kidney Disease	Development of Chronic Kidney Disease	60 days and 1 year after ICU admission
Secondary	SOFA-score	Sequential Organ Failure Score as a continuous variable	During Intensive Care, an estimated average of 10 days.
Secondary	Thromboembolic events	Occurence of thrombosis and/or embolous	During intensive care
Secondary	ICUAW	Intensive care acquired weakness	During intensive care or after intensive care